Lucence has a total of 30 patents globally, out of which 3 have been granted. Of these 30 patents, more than 90% patents are active. Singapore is where Lucence has filed the maximum number of patents, followed by the USA and Europe. Parallelly, Singapore seems to be the main focused R&D center and also USA is the origin country of Lucence.
Lucence was founded in 2016 Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients with life-changing information.
Do read about some of the most popular patents of Lucence which have been covered by us in this article and also you can find Lucence patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over the Lucence patent portfolio.
How many patents does Lucence have?
Lucence has a total of 30 patents globally. These patents belong to 13 unique patent families. Out of 30 patents, 27 patents are active.
How Many Patents did Lucence File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
|Year of Patents Filing or Grant||Lucence Applications Filed||Lucence Patents Granted|
How many Lucence patents are Alive/Dead?
How Many Patents did Lucence File in Different Countries?
Countries in which Lucence Filed Patents
|United States Of America||5|
|Hong Kong (S.A.R.)||3|
Where are Research Centers of Lucence Patents Located?
List of Lucence Patents –
|US20180073083A1||A Multigene Assay|
|US20160230234A1||Multigene Assay For Prognosis Of Renal Cancer|
|US20220117587A1||Method Of Sample Collection|
|US20210180125A1||Method For The Detection And Quantification Of Genetic Alterations|
|US20190085417A1||Detection And Quantification Of Target Nucleic Acid Sequence Of A Microorganism|
|EP3268495A1||A Multigene Assay|
|EP3047040A1||Multigene Assay For Prognosis Of Renal Cancer|
|EP3390672A1||Detection And Quantification Of Target Nucleic Acid Sequence Of A Microorganism|
|EP3810805A1||Method For Detection And Quantification Of Genetic Alterations|
|WO2020005159A1||Method For Detection And Quantification Of Genetic Alterations|
|WO2022025824A1||Methods For Detecting Rna Viruses|
|WO2022025825A1||Methods And Kits For Determining Integrity Of Viral Rna|
|WO2022025826A1||Method Of Sample Collection|
|WO2022025823A1||Methods And Kits For Detecting And Sequencing Rna Viruses|
|WO2022035382A1||Automated Sample Pre-Processing System And Method|
|MYPI2018000933A0||Detection And Quantification Of Target Nucleic Acid Sequence Of A Microorganism|
|SG11201707067UA||A Multigene Assay|
|SG11201602019XA||Multigene Assay For Prognosis Of Renal Cancer|
|SG11201805115PA||Detection And Quantification Of Target Nucleic Acid Sequence Of A Microorganism|
|SG11202012687SA||Method For Detection And Quantification Of Genetic Alterations|
|SG10202108293WA||Method Of Sample Collection|
|SG10202007826SA||Method For Automated Workflow For Saliva And Sputum Sample Solubilization, Pooling And Pre-Concentration To Enhance Molecular Testing Of Nucleic Acid Viruses|
|SG10202007267SA||Non-Invasive Naso-Oropharyngeal (Nop) Saliva Collection And Transport In Stabilization Fluid To Enhance Molecular Diagnostic Testing Of Rna Viruses|
|SG10202007270PA||Method Of Sensitive Detection And Sequencing Of Rna Viruses|
|DE602014058377T2||Multigentest For The Forecast Of Renal Cancer|
|DE602016058601T2||Detection And Quantification Of A Target Nucleic Acid Sequence Of A Microorganism|
|HK1248771A||A Multigene Assay|
|HK1263315A||Detection And Quantification Of Target Nucleic Acid Sequence Of A Microorganism|
|HK40045286A||Method For Detection And Quantification Of Genetic Alterations|